Chelidonic acid ameliorates atopic dermatitis symptoms through suppression the inflammatory mediators in in vivo and in vitro

Abstract

Abstract Chelidonic acid (CA), a γ-pyrone compound, exerts various pharmacological functions, including anti-allergic and anti-colitis activities. However, the anti-atopic effect of CA and the mechanisms involved therein are not completely understood. The aim of the present study was to elucidate whether CA modulates atopic dermatitis (AD) in vitro and in vivo. We examined the pharmacological effects of CA on compound 48/80- or histamine-induced scratching behaviors and 2, 4-dinitrochlrobenzene-induced AD-like skin lesions in mice. Additionally, we evaluated the regulatory effects of CA on the expression of tumor necrosis factor -α, interleukin-6, cyclooxygenase -2 and inducible nitric oxide synthase and activation of nuclear factor-kappa B (NF-κB) in vivo and in vitro. The results showed that CA inhibited the symptoms of AD such as itching, eczema, erythema and dryness, and decreased the serum levels of IgE and histamine in mice. The inhibition rates of IgE and histamine levels by CA (2 mg/kg) were approximately 36.21 ± 4.19% and 28.93 ± 6.16%, respectively. Moreover, CA significantly attenuated the expression of inflammatory-related genes and NF-κB activation in AD-like skin lesions and mouse peritoneal macrophages. The maximal inhibition rates of NF-κB activation by CA were approximately 42.05 ± 2.12% (in AD-like skin lesions) and 37.17 ± 6.12% (in LPS-stimulated peritoneal macrophages), respectively. These results suggest that CA may be a useful therapeutic agent for skin inflammatory condition such as AD.

Keywords

• Chelidonic acid
• Atopic dermatitis
• Inflammatory mediators